Skip Navigation LinksHome > May 2007 - Volume 26 - Issue 5 > VALGANCICLOVIR FOR CONGENITAL CMV INFECTION: A PILOT STUDY O...
Pediatric Infectious Disease Journal:
doi: 10.1097/01.inf.0000261111.90075.4d
Brief Reports

VALGANCICLOVIR FOR CONGENITAL CMV INFECTION: A PILOT STUDY ON PLASMA CONCENTRATION IN NEWBORNS AND INFANTS

Galli, Luisa MD*; Novelli, Andrea MD†; Chiappini, Elena PhD*; Gervaso, Paola MD*; Cassetta, Maria Iris BS†; Fallani, Stefania BS†; de Martino, Maurizio MD*

Collapse Box

Abstract

The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.

© 2007 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.